EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanomedicine is more than a supporting role in rheumatoid arthritis therapy

Yu Han, Shilei Huang

Journal of Controlled Release · 2023-04 · 356 · 142-161

DOI: 10.1016/j.jconrel.2023.02.035 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-04. Verfasst von Yu Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: fcchanyu@zzu.edu.cn. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 188 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis(RA) is an autoimmune disorder that affects the joints. Various medications successfully alleviate the symptoms of RA in clinical. Still, few therapy strategies can cure RA, especially when joint destruction begins, and there is currently no effective bone-protective treatment to reverse the articular damage. Furthermore, the RA medications now used in clinical practice accompany various adverse side effects. Nanotechnology can improve the pharmacokinetics of traditional anti-RA drugs and therapeutic precision through targeting modification. Although the clinical application of nanomedicines for RA is in its infancy, preclinical research is rising. Current anti-RA nano-drug studies mainly focus on the following: drug delivery systems, nanomedicines with anti-inflammatory and anti-arthritic properties, biomimetic design with better biocompatibility and therapeutic features, and nanoparticle-dominated energy conversion therapies. These therapies have shown promising therapeutic benefits in animal models, indicating that nanomedicines are a potential solution to the current bottleneck in RA treatment. This review will summarize the present state of anti-RA nano-drug research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsAnimalsNanomedicineNanotechnologyJointsDrug Delivery Systems

Stichwörter der Autor:innen

Augmented nano-therapyDMARDsNanomedicineNanoparticlesRheumatoid arthritisTherapeutic nano-drugsTreat-to-target

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: fcchanyu@zzu.edu.cn.
  • Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Zitieren

APA

Han, Y., & Huang, S. (2023). Nanomedicine is more than a supporting role in rheumatoid arthritis therapy. Journal of Controlled Release, 356, 142-161. https://doi.org/10.1016/j.jconrel.2023.02.035

Vancouver

Han Y, Huang S. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy. Journal of Controlled Release. 2023;356:142-161. doi:10.1016/j.jconrel.2023.02.035

BibTeX
@article{Han2023,
  author = {Han, Yu and Huang, Shilei},
  title = {Nanomedicine is more than a supporting role in rheumatoid arthritis therapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {356},
  pages = {142--161},
  doi = {10.1016/j.jconrel.2023.02.035}
}
Kostenlos starten →